Evercore analyst Gavin Clark-Gartner maintains $argenx SE (ARGX.US)$ with a buy rating, and maintains the target price at $706.
According to TipRanks data, the analyst has a success rate of 46.3% and a total average return of 22.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $argenx SE (ARGX.US)$'s main analysts recently are as follows:
The continuation of Phase 3 across all three myositis subtypes is seen as a positive factor that could enhance future pipeline value, though it may not significantly impact stock movement immediately. The analysis included a 70% probability of success for myositis, with adjustments anticipated upon the release of full data at an upcoming medical conference.
Argenx's announcement about achieving clinical proof-of-concept in myositis with subQ efgart showing statistically significant improvement across all three evaluated myositis subtypes in Phase 2 has been positively noted. This development is seen as enhancing Argenx's position in the autoimmune sector, and detailed results are anticipated at a future medical conference.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析师Gavin Clark-Gartner维持$argenx SE (ARGX.US)$买入评级，维持目标价706美元。
根据TipRanks数据显示，该分析师近一年总胜率为46.3%，总平均回报率为22.2%。
此外，综合报道，$argenx SE (ARGX.US)$近期主要分析师观点如下：
在所有三种肌炎亚型的第3阶段持续被视为一个积极因素，这可能增强未来的管道价值，尽管这可能不会立即对股票波动产生显著影响。分析中包括肌炎成功的概率为70%，预计在即将举行的医疗会议上公布完整数据时会进行调整。
Argenx宣布在肌炎领域通过皮下efgart获得临床概念证明，该治疗在第二阶段中显示所有三种评估肌炎亚型均有统计学显著改善，这一进展被积极评价。此发展被视为增强Argenx在自身免疫板块中的地位，详细结果预计将在未来的医疗会议上公布。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
